{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"3.5","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"PFS will be estimated using standard Kaplan-Meier methods for censored data, from which the median and other statistics of interest will be calculated (e.g., rates at 3 months, 6 months, 12 months).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nNintedanib: Given PO","id":"OG000","title":"Treatment (Nintedanib)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause; assessed up to 4 months","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}